29 September 2016 - The Institute for Clinical and Economic Review has released a draft evidence report assessing the comparative clinical effectiveness and value of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis.

The report, as well as accompanying draft voting questions, will be open to public comment for four weeks.

The Institute for Clinical and Economic Review (ICER) is committed to engaging with all stakeholders in a thorough and transparent manner. Before completing this draft evidence report, ICER reached out to key stakeholders, including patient groups, clinical experts, and the manufacturers of the drugs under review to engage them in the process. ICER also opened a draft scoping cocument to public comment for a three-week period. The current draft report incorporates input received from patients, clinicians, manufacturers, and other stakeholders through each of these opportunities for engagement.

The Draft Evidence Report, as well as the accompanying voting questions, will be open to public comment until October 20, 2016. All stakeholders are invited to submit formal comments by email to publiccomments@icer-review.org. Guidelines for submitting public comments, including formatting specifications, are available on the ICER website.

ICER will review all comments received and incorporate any needed changes in the Evidence Report that will be posted on or about November 4, 2016. All comments will be posted publicly along with the evidence report.

Read ICER draft evidence report